nodes	percent_of_prediction	percent_of_DWPC	metapath
Azelastine—CYP3A5—prostate cancer	0.08	0.225	CbGaD
Azelastine—CYP2A6—prostate cancer	0.0774	0.218	CbGaD
Azelastine—CYP2E1—prostate cancer	0.055	0.155	CbGaD
Azelastine—CYP2C19—prostate cancer	0.0544	0.153	CbGaD
Azelastine—CYP1A1—prostate cancer	0.0542	0.152	CbGaD
Azelastine—CYP3A4—prostate cancer	0.0346	0.0973	CbGaD
Azelastine—CYP1A1—Flutamide—prostate cancer	0.0209	0.0511	CbGbCtD
Azelastine—CYP1A1—Estrone—prostate cancer	0.0151	0.037	CbGbCtD
Azelastine—CYP2C8—Nilutamide—prostate cancer	0.0145	0.0356	CbGbCtD
Azelastine—CYP3A5—Flutamide—prostate cancer	0.0125	0.0307	CbGbCtD
Azelastine—CYP2C19—Nilutamide—prostate cancer	0.0122	0.0299	CbGbCtD
Azelastine—CYP2C19—Bicalutamide—prostate cancer	0.0122	0.0299	CbGbCtD
Azelastine—CYP2C8—Abiraterone—prostate cancer	0.0121	0.0295	CbGbCtD
Azelastine—ADRA1B—vas deferens—prostate cancer	0.0117	0.361	CbGeAlD
Azelastine—CYP2E1—Estrone—prostate cancer	0.0117	0.0285	CbGbCtD
Azelastine—CYP2B6—Estrone—prostate cancer	0.0115	0.0282	CbGbCtD
Azelastine—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.0112	0.0275	CbGbCtD
Azelastine—CYP2B6—Ethinyl Estradiol—prostate cancer	0.0103	0.0251	CbGbCtD
Azelastine—CYP2C9—Nilutamide—prostate cancer	0.0101	0.0248	CbGbCtD
Azelastine—CYP2C9—Bicalutamide—prostate cancer	0.0101	0.0248	CbGbCtD
Azelastine—CYP2C19—Flutamide—prostate cancer	0.0101	0.0247	CbGbCtD
Azelastine—CYP1A2—Flutamide—prostate cancer	0.00933	0.0228	CbGbCtD
Azelastine—CYP2D6—Bicalutamide—prostate cancer	0.00928	0.0227	CbGbCtD
Azelastine—CYP3A5—Cabazitaxel—prostate cancer	0.00927	0.0227	CbGbCtD
Azelastine—ABCB1—Estramustine—prostate cancer	0.00915	0.0224	CbGbCtD
Azelastine—CYP3A5—Estrone—prostate cancer	0.00906	0.0222	CbGbCtD
Azelastine—CYP2C8—Cabazitaxel—prostate cancer	0.00891	0.0218	CbGbCtD
Azelastine—CYP1A1—Estradiol—prostate cancer	0.00867	0.0212	CbGbCtD
Azelastine—CYP2C8—Ethinyl Estradiol—prostate cancer	0.00777	0.019	CbGbCtD
Azelastine—CYP2D6—Abiraterone—prostate cancer	0.00769	0.0188	CbGbCtD
Azelastine—CYP2E1—Mitoxantrone—prostate cancer	0.00693	0.017	CbGbCtD
Azelastine—CYP1A2—Estrone—prostate cancer	0.00674	0.0165	CbGbCtD
Azelastine—CYP2C9—Estrone—prostate cancer	0.00608	0.0149	CbGbCtD
Azelastine—ABCB1—Cabazitaxel—prostate cancer	0.00603	0.0148	CbGbCtD
Azelastine—CYP3A4—Bicalutamide—prostate cancer	0.0059	0.0144	CbGbCtD
Azelastine—ABCB1—Estrone—prostate cancer	0.0059	0.0144	CbGbCtD
Azelastine—CYP3A4—Estramustine—prostate cancer	0.00548	0.0134	CbGbCtD
Azelastine—ABCB1—Ethinyl Estradiol—prostate cancer	0.00526	0.0129	CbGbCtD
Azelastine—CYP3A5—Estradiol—prostate cancer	0.0052	0.0127	CbGbCtD
Azelastine—CYP2C8—Estradiol—prostate cancer	0.005	0.0123	CbGbCtD
Azelastine—CYP3A4—Flutamide—prostate cancer	0.00489	0.012	CbGbCtD
Azelastine—CYP3A4—Abiraterone—prostate cancer	0.00489	0.012	CbGbCtD
Azelastine—CYP2C9—Capecitabine—prostate cancer	0.00461	0.0113	CbGbCtD
Azelastine—CYP1A2—Conjugated Estrogens—prostate cancer	0.00441	0.0108	CbGbCtD
Azelastine—CYP2E1—Etoposide—prostate cancer	0.00437	0.0107	CbGbCtD
Azelastine—CYP2C19—Estradiol—prostate cancer	0.0042	0.0103	CbGbCtD
Azelastine—CYP1A2—Estradiol—prostate cancer	0.00387	0.00948	CbGbCtD
Azelastine—ABCB1—Conjugated Estrogens—prostate cancer	0.00386	0.00944	CbGbCtD
Azelastine—CYP3A4—Cabazitaxel—prostate cancer	0.00362	0.00885	CbGbCtD
Azelastine—CYP2C19—Prednisone—prostate cancer	0.00361	0.00884	CbGbCtD
Azelastine—CYP3A4—Estrone—prostate cancer	0.00353	0.00865	CbGbCtD
Azelastine—ABCB1—Mitoxantrone—prostate cancer	0.00351	0.00859	CbGbCtD
Azelastine—CYP2C9—Estradiol—prostate cancer	0.00349	0.00854	CbGbCtD
Azelastine—CYP3A5—Etoposide—prostate cancer	0.0034	0.00832	CbGbCtD
Azelastine—ABCB1—Estradiol—prostate cancer	0.00339	0.00829	CbGbCtD
Azelastine—CYP2C8—Etoposide—prostate cancer	0.00327	0.008	CbGbCtD
Azelastine—CYP3A4—Ethinyl Estradiol—prostate cancer	0.00315	0.00771	CbGbCtD
Azelastine—CYP3A5—Docetaxel—prostate cancer	0.00311	0.00761	CbGbCtD
Azelastine—CYP2B6—Doxorubicin—prostate cancer	0.00294	0.0072	CbGbCtD
Azelastine—ABCB1—Prednisone—prostate cancer	0.00291	0.00713	CbGbCtD
Azelastine—CYP1A2—Etoposide—prostate cancer	0.00253	0.00619	CbGbCtD
Azelastine—CYP3A4—Conjugated Estrogens—prostate cancer	0.00231	0.00566	CbGbCtD
Azelastine—ABCB1—Etoposide—prostate cancer	0.00221	0.00541	CbGbCtD
Azelastine—CYP3A4—Mitoxantrone—prostate cancer	0.0021	0.00514	CbGbCtD
Azelastine—CYP3A4—Estradiol—prostate cancer	0.00203	0.00497	CbGbCtD
Azelastine—ABCB1—Docetaxel—prostate cancer	0.00202	0.00495	CbGbCtD
Azelastine—CYP3A4—Prednisone—prostate cancer	0.00175	0.00427	CbGbCtD
Azelastine—CYP2C19—urine—prostate cancer	0.00166	0.0511	CbGeAlD
Azelastine—ABCB1—Doxorubicin—prostate cancer	0.00151	0.00369	CbGbCtD
Azelastine—CYP2D6—Doxorubicin—prostate cancer	0.00142	0.00348	CbGbCtD
Azelastine—CYP1A2—urine—prostate cancer	0.00136	0.0417	CbGeAlD
Azelastine—CYP3A4—Etoposide—prostate cancer	0.00133	0.00324	CbGbCtD
Azelastine—CYP2C9—urine—prostate cancer	0.00129	0.0396	CbGeAlD
Azelastine—CYP2E1—urine—prostate cancer	0.00122	0.0375	CbGeAlD
Azelastine—CYP3A4—Docetaxel—prostate cancer	0.00121	0.00297	CbGbCtD
Azelastine—CYP3A4—urine—prostate cancer	0.000981	0.0302	CbGeAlD
Azelastine—CYP2D6—urine—prostate cancer	0.000965	0.0297	CbGeAlD
Azelastine—CYP2A6—prostate gland—prostate cancer	0.000926	0.0285	CbGeAlD
Azelastine—CYP3A4—Doxorubicin—prostate cancer	0.000904	0.00221	CbGbCtD
Azelastine—CYP2A6—seminal vesicle—prostate cancer	0.000783	0.0241	CbGeAlD
Azelastine—ADRA1B—renal system—prostate cancer	0.000714	0.022	CbGeAlD
Azelastine—KCNH2—prostate gland—prostate cancer	0.000568	0.0175	CbGeAlD
Azelastine—KCNH2—seminal vesicle—prostate cancer	0.000481	0.0148	CbGeAlD
Azelastine—CYP3A5—prostate gland—prostate cancer	0.000469	0.0144	CbGeAlD
Azelastine—HRH1—prostate gland—prostate cancer	0.000455	0.014	CbGeAlD
Azelastine—CYP2E1—prostate gland—prostate cancer	0.000438	0.0135	CbGeAlD
Azelastine—KCNH2—renal system—prostate cancer	0.000387	0.0119	CbGeAlD
Azelastine—KCNH2—urethra—prostate cancer	0.00038	0.0117	CbGeAlD
Azelastine—CYP2E1—seminal vesicle—prostate cancer	0.00037	0.0114	CbGeAlD
Azelastine—CYP2C8—renal system—prostate cancer	0.000354	0.0109	CbGeAlD
Azelastine—CYP1A1—epithelium—prostate cancer	0.000353	0.0109	CbGeAlD
Azelastine—HRH1—epithelium—prostate cancer	0.000335	0.0103	CbGeAlD
Azelastine—CYP1A2—renal system—prostate cancer	0.000332	0.0102	CbGeAlD
Azelastine—CYP1A1—renal system—prostate cancer	0.000327	0.0101	CbGeAlD
Azelastine—CYP1A1—urethra—prostate cancer	0.000321	0.00989	CbGeAlD
Azelastine—CYP3A5—renal system—prostate cancer	0.00032	0.00984	CbGeAlD
Azelastine—CYP2B6—renal system—prostate cancer	0.000318	0.00978	CbGeAlD
Azelastine—HRH1—urethra—prostate cancer	0.000305	0.00938	CbGeAlD
Azelastine—CYP2E1—renal system—prostate cancer	0.000298	0.00918	CbGeAlD
Azelastine—CYP2E1—urethra—prostate cancer	0.000293	0.00902	CbGeAlD
Azelastine—KCNH2—bone marrow—prostate cancer	0.000293	0.00901	CbGeAlD
Azelastine—KCNH2—testis—prostate cancer	0.00025	0.0077	CbGeAlD
Azelastine—ABCB1—prostate gland—prostate cancer	0.000249	0.00767	CbGeAlD
Azelastine—CYP3A4—renal system—prostate cancer	0.00024	0.00739	CbGeAlD
Azelastine—CYP2D6—renal system—prostate cancer	0.000236	0.00727	CbGeAlD
Azelastine—CYP2C8—testis—prostate cancer	0.000229	0.00705	CbGeAlD
Azelastine—ABCB1—seminal vesicle—prostate cancer	0.000211	0.00649	CbGeAlD
Azelastine—CYP2B6—testis—prostate cancer	0.000205	0.00632	CbGeAlD
Azelastine—HRH1—testis—prostate cancer	0.000201	0.00617	CbGeAlD
Azelastine—CYP2E1—testis—prostate cancer	0.000193	0.00593	CbGeAlD
Azelastine—ABCB1—epithelium—prostate cancer	0.000183	0.00564	CbGeAlD
Azelastine—KCNH2—lymph node—prostate cancer	0.000181	0.00558	CbGeAlD
Azelastine—ABCB1—renal system—prostate cancer	0.00017	0.00523	CbGeAlD
Azelastine—ABCB1—urethra—prostate cancer	0.000167	0.00514	CbGeAlD
Azelastine—CYP1A1—lymph node—prostate cancer	0.000153	0.00472	CbGeAlD
Azelastine—CYP2D6—testis—prostate cancer	0.000153	0.0047	CbGeAlD
Azelastine—HRH1—lymph node—prostate cancer	0.000145	0.00448	CbGeAlD
Azelastine—ABCB1—bone marrow—prostate cancer	0.000128	0.00395	CbGeAlD
Azelastine—ABCB1—testis—prostate cancer	0.00011	0.00338	CbGeAlD
Azelastine—Clemastine—CYP3A4—prostate cancer	9.07e-05	0.237	CrCbGaD
Azelastine—ABCB1—lymph node—prostate cancer	7.96e-05	0.00245	CbGeAlD
Azelastine—Clozapine—CYP1B1—prostate cancer	6.91e-05	0.181	CrCbGaD
Azelastine—Clozapine—CYP2A6—prostate cancer	5.33e-05	0.139	CrCbGaD
Azelastine—Bronchitis—Epirubicin—prostate cancer	4.98e-05	0.000451	CcSEcCtD
Azelastine—Nasopharyngitis—Doxorubicin—prostate cancer	4.95e-05	0.000449	CcSEcCtD
Azelastine—Eye disorder—Prednisone—prostate cancer	4.95e-05	0.000448	CcSEcCtD
Azelastine—Flushing—Prednisone—prostate cancer	4.91e-05	0.000445	CcSEcCtD
Azelastine—Alanine aminotransferase increased—Doxorubicin—prostate cancer	4.89e-05	0.000442	CcSEcCtD
Azelastine—Vision blurred—Capecitabine—prostate cancer	4.88e-05	0.000442	CcSEcCtD
Azelastine—Asthenia—Estradiol—prostate cancer	4.86e-05	0.00044	CcSEcCtD
Azelastine—Upper respiratory tract infection—Epirubicin—prostate cancer	4.81e-05	0.000435	CcSEcCtD
Azelastine—Ill-defined disorder—Capecitabine—prostate cancer	4.8e-05	0.000435	CcSEcCtD
Azelastine—Pruritus—Estradiol—prostate cancer	4.79e-05	0.000434	CcSEcCtD
Azelastine—Asthma—Doxorubicin—prostate cancer	4.79e-05	0.000434	CcSEcCtD
Azelastine—Pollakiuria—Epirubicin—prostate cancer	4.78e-05	0.000433	CcSEcCtD
Azelastine—Palpitations—Docetaxel—prostate cancer	4.72e-05	0.000428	CcSEcCtD
Azelastine—Paraesthesia—Etoposide—prostate cancer	4.71e-05	0.000427	CcSEcCtD
Azelastine—Weight increased—Epirubicin—prostate cancer	4.71e-05	0.000426	CcSEcCtD
Azelastine—Dyspnoea—Etoposide—prostate cancer	4.68e-05	0.000424	CcSEcCtD
Azelastine—Malaise—Capecitabine—prostate cancer	4.67e-05	0.000423	CcSEcCtD
Azelastine—Somnolence—Etoposide—prostate cancer	4.67e-05	0.000423	CcSEcCtD
Azelastine—Cough—Docetaxel—prostate cancer	4.66e-05	0.000422	CcSEcCtD
Azelastine—Vertigo—Capecitabine—prostate cancer	4.65e-05	0.000421	CcSEcCtD
Azelastine—Hypersensitivity—Mitoxantrone—prostate cancer	4.65e-05	0.000421	CcSEcCtD
Azelastine—Diarrhoea—Estradiol—prostate cancer	4.63e-05	0.00042	CcSEcCtD
Azelastine—Hypertension—Docetaxel—prostate cancer	4.61e-05	0.000418	CcSEcCtD
Azelastine—Bronchitis—Doxorubicin—prostate cancer	4.6e-05	0.000417	CcSEcCtD
Azelastine—Palpitations—Capecitabine—prostate cancer	4.57e-05	0.000414	CcSEcCtD
Azelastine—Chest pain—Docetaxel—prostate cancer	4.55e-05	0.000412	CcSEcCtD
Azelastine—Myalgia—Docetaxel—prostate cancer	4.55e-05	0.000412	CcSEcCtD
Azelastine—Asthenia—Mitoxantrone—prostate cancer	4.53e-05	0.00041	CcSEcCtD
Azelastine—Fatigue—Etoposide—prostate cancer	4.53e-05	0.00041	CcSEcCtD
Azelastine—Cough—Capecitabine—prostate cancer	4.52e-05	0.000409	CcSEcCtD
Azelastine—Constipation—Etoposide—prostate cancer	4.49e-05	0.000406	CcSEcCtD
Azelastine—Pain—Etoposide—prostate cancer	4.49e-05	0.000406	CcSEcCtD
Azelastine—Conjunctivitis—Epirubicin—prostate cancer	4.48e-05	0.000406	CcSEcCtD
Azelastine—Dizziness—Estradiol—prostate cancer	4.48e-05	0.000406	CcSEcCtD
Azelastine—Hypertension—Capecitabine—prostate cancer	4.47e-05	0.000405	CcSEcCtD
Azelastine—Dry mouth—Docetaxel—prostate cancer	4.45e-05	0.000403	CcSEcCtD
Azelastine—Upper respiratory tract infection—Doxorubicin—prostate cancer	4.45e-05	0.000403	CcSEcCtD
Azelastine—Pollakiuria—Doxorubicin—prostate cancer	4.42e-05	0.0004	CcSEcCtD
Azelastine—Myalgia—Capecitabine—prostate cancer	4.41e-05	0.000399	CcSEcCtD
Azelastine—Chest pain—Capecitabine—prostate cancer	4.41e-05	0.000399	CcSEcCtD
Azelastine—Haematuria—Epirubicin—prostate cancer	4.4e-05	0.000398	CcSEcCtD
Azelastine—Confusional state—Docetaxel—prostate cancer	4.4e-05	0.000398	CcSEcCtD
Azelastine—Anxiety—Capecitabine—prostate cancer	4.39e-05	0.000398	CcSEcCtD
Azelastine—Anaphylactic shock—Docetaxel—prostate cancer	4.36e-05	0.000395	CcSEcCtD
Azelastine—Weight increased—Doxorubicin—prostate cancer	4.36e-05	0.000395	CcSEcCtD
Azelastine—Discomfort—Capecitabine—prostate cancer	4.35e-05	0.000394	CcSEcCtD
Azelastine—Epistaxis—Epirubicin—prostate cancer	4.35e-05	0.000394	CcSEcCtD
Azelastine—Vision blurred—Prednisone—prostate cancer	4.34e-05	0.000393	CcSEcCtD
Azelastine—Infection—Docetaxel—prostate cancer	4.33e-05	0.000392	CcSEcCtD
Azelastine—Sinusitis—Epirubicin—prostate cancer	4.33e-05	0.000392	CcSEcCtD
Azelastine—Feeling abnormal—Etoposide—prostate cancer	4.33e-05	0.000392	CcSEcCtD
Azelastine—Diarrhoea—Mitoxantrone—prostate cancer	4.32e-05	0.000391	CcSEcCtD
Azelastine—Dry mouth—Capecitabine—prostate cancer	4.31e-05	0.00039	CcSEcCtD
Azelastine—Vomiting—Estradiol—prostate cancer	4.31e-05	0.00039	CcSEcCtD
Azelastine—Gastrointestinal pain—Etoposide—prostate cancer	4.29e-05	0.000389	CcSEcCtD
Azelastine—Ill-defined disorder—Prednisone—prostate cancer	4.28e-05	0.000387	CcSEcCtD
Azelastine—Rash—Estradiol—prostate cancer	4.27e-05	0.000387	CcSEcCtD
Azelastine—Dermatitis—Estradiol—prostate cancer	4.27e-05	0.000386	CcSEcCtD
Azelastine—Confusional state—Capecitabine—prostate cancer	4.26e-05	0.000386	CcSEcCtD
Azelastine—Tachycardia—Docetaxel—prostate cancer	4.26e-05	0.000386	CcSEcCtD
Azelastine—Headache—Estradiol—prostate cancer	4.24e-05	0.000384	CcSEcCtD
Azelastine—Agitation—Prednisone—prostate cancer	4.24e-05	0.000384	CcSEcCtD
Azelastine—Infection—Capecitabine—prostate cancer	4.2e-05	0.00038	CcSEcCtD
Azelastine—Malaise—Prednisone—prostate cancer	4.16e-05	0.000376	CcSEcCtD
Azelastine—Rhinitis—Epirubicin—prostate cancer	4.15e-05	0.000376	CcSEcCtD
Azelastine—Abdominal pain—Etoposide—prostate cancer	4.15e-05	0.000376	CcSEcCtD
Azelastine—Body temperature increased—Etoposide—prostate cancer	4.15e-05	0.000376	CcSEcCtD
Azelastine—Conjunctivitis—Doxorubicin—prostate cancer	4.15e-05	0.000376	CcSEcCtD
Azelastine—Vertigo—Prednisone—prostate cancer	4.14e-05	0.000375	CcSEcCtD
Azelastine—Tachycardia—Capecitabine—prostate cancer	4.12e-05	0.000373	CcSEcCtD
Azelastine—Hypoaesthesia—Epirubicin—prostate cancer	4.12e-05	0.000373	CcSEcCtD
Azelastine—Pharyngitis—Epirubicin—prostate cancer	4.11e-05	0.000372	CcSEcCtD
Azelastine—Haematuria—Doxorubicin—prostate cancer	4.07e-05	0.000369	CcSEcCtD
Azelastine—Epistaxis—Doxorubicin—prostate cancer	4.03e-05	0.000365	CcSEcCtD
Azelastine—Nausea—Estradiol—prostate cancer	4.02e-05	0.000364	CcSEcCtD
Azelastine—Vomiting—Mitoxantrone—prostate cancer	4.01e-05	0.000363	CcSEcCtD
Azelastine—Sinusitis—Doxorubicin—prostate cancer	4e-05	0.000363	CcSEcCtD
Azelastine—Visual impairment—Epirubicin—prostate cancer	3.99e-05	0.000361	CcSEcCtD
Azelastine—Hypertension—Prednisone—prostate cancer	3.98e-05	0.00036	CcSEcCtD
Azelastine—Rash—Mitoxantrone—prostate cancer	3.98e-05	0.00036	CcSEcCtD
Azelastine—Dermatitis—Mitoxantrone—prostate cancer	3.97e-05	0.00036	CcSEcCtD
Azelastine—Musculoskeletal discomfort—Docetaxel—prostate cancer	3.97e-05	0.00036	CcSEcCtD
Azelastine—Headache—Mitoxantrone—prostate cancer	3.95e-05	0.000358	CcSEcCtD
Azelastine—Myalgia—Prednisone—prostate cancer	3.92e-05	0.000355	CcSEcCtD
Azelastine—Paraesthesia—Docetaxel—prostate cancer	3.92e-05	0.000355	CcSEcCtD
Azelastine—Anxiety—Prednisone—prostate cancer	3.91e-05	0.000354	CcSEcCtD
Azelastine—Dyspnoea—Docetaxel—prostate cancer	3.89e-05	0.000352	CcSEcCtD
Azelastine—Somnolence—Docetaxel—prostate cancer	3.88e-05	0.000351	CcSEcCtD
Azelastine—Discomfort—Prednisone—prostate cancer	3.88e-05	0.000351	CcSEcCtD
Azelastine—Eye disorder—Epirubicin—prostate cancer	3.87e-05	0.00035	CcSEcCtD
Azelastine—Hypersensitivity—Etoposide—prostate cancer	3.87e-05	0.00035	CcSEcCtD
Azelastine—Musculoskeletal discomfort—Capecitabine—prostate cancer	3.85e-05	0.000348	CcSEcCtD
Azelastine—Flushing—Epirubicin—prostate cancer	3.84e-05	0.000348	CcSEcCtD
Azelastine—Rhinitis—Doxorubicin—prostate cancer	3.84e-05	0.000348	CcSEcCtD
Azelastine—Hypoaesthesia—Doxorubicin—prostate cancer	3.81e-05	0.000345	CcSEcCtD
Azelastine—Pharyngitis—Doxorubicin—prostate cancer	3.8e-05	0.000344	CcSEcCtD
Azelastine—Paraesthesia—Capecitabine—prostate cancer	3.79e-05	0.000343	CcSEcCtD
Azelastine—Clozapine—CYP2E1—prostate cancer	3.78e-05	0.099	CrCbGaD
Azelastine—Asthenia—Etoposide—prostate cancer	3.77e-05	0.000341	CcSEcCtD
Azelastine—Dyspnoea—Capecitabine—prostate cancer	3.77e-05	0.000341	CcSEcCtD
Azelastine—Anaphylactic shock—Prednisone—prostate cancer	3.76e-05	0.000341	CcSEcCtD
Azelastine—Fatigue—Docetaxel—prostate cancer	3.76e-05	0.000341	CcSEcCtD
Azelastine—Nausea—Mitoxantrone—prostate cancer	3.75e-05	0.000339	CcSEcCtD
Azelastine—Clozapine—CYP2C19—prostate cancer	3.75e-05	0.098	CrCbGaD
Azelastine—Infection—Prednisone—prostate cancer	3.74e-05	0.000338	CcSEcCtD
Azelastine—Clozapine—CYP1A1—prostate cancer	3.73e-05	0.0976	CrCbGaD
Azelastine—Pain—Docetaxel—prostate cancer	3.73e-05	0.000338	CcSEcCtD
Azelastine—Constipation—Docetaxel—prostate cancer	3.73e-05	0.000338	CcSEcCtD
Azelastine—Pruritus—Etoposide—prostate cancer	3.71e-05	0.000336	CcSEcCtD
Azelastine—Visual impairment—Doxorubicin—prostate cancer	3.69e-05	0.000334	CcSEcCtD
Azelastine—Tachycardia—Prednisone—prostate cancer	3.67e-05	0.000332	CcSEcCtD
Azelastine—Fatigue—Capecitabine—prostate cancer	3.64e-05	0.00033	CcSEcCtD
Azelastine—Constipation—Capecitabine—prostate cancer	3.61e-05	0.000327	CcSEcCtD
Azelastine—Pain—Capecitabine—prostate cancer	3.61e-05	0.000327	CcSEcCtD
Azelastine—Feeling abnormal—Docetaxel—prostate cancer	3.59e-05	0.000326	CcSEcCtD
Azelastine—Diarrhoea—Etoposide—prostate cancer	3.59e-05	0.000325	CcSEcCtD
Azelastine—Eye disorder—Doxorubicin—prostate cancer	3.58e-05	0.000324	CcSEcCtD
Azelastine—Gastrointestinal pain—Docetaxel—prostate cancer	3.57e-05	0.000323	CcSEcCtD
Azelastine—Flushing—Doxorubicin—prostate cancer	3.56e-05	0.000322	CcSEcCtD
Azelastine—Tension—Epirubicin—prostate cancer	3.54e-05	0.00032	CcSEcCtD
Azelastine—Dysgeusia—Epirubicin—prostate cancer	3.53e-05	0.00032	CcSEcCtD
Azelastine—Nervousness—Epirubicin—prostate cancer	3.5e-05	0.000317	CcSEcCtD
Azelastine—Back pain—Epirubicin—prostate cancer	3.49e-05	0.000316	CcSEcCtD
Azelastine—Feeling abnormal—Capecitabine—prostate cancer	3.48e-05	0.000315	CcSEcCtD
Azelastine—Dizziness—Etoposide—prostate cancer	3.47e-05	0.000314	CcSEcCtD
Azelastine—Gastrointestinal pain—Capecitabine—prostate cancer	3.45e-05	0.000313	CcSEcCtD
Azelastine—Abdominal pain—Docetaxel—prostate cancer	3.45e-05	0.000312	CcSEcCtD
Azelastine—Body temperature increased—Docetaxel—prostate cancer	3.45e-05	0.000312	CcSEcCtD
Azelastine—Musculoskeletal discomfort—Prednisone—prostate cancer	3.43e-05	0.00031	CcSEcCtD
Azelastine—Vision blurred—Epirubicin—prostate cancer	3.4e-05	0.000308	CcSEcCtD
Azelastine—Paraesthesia—Prednisone—prostate cancer	3.38e-05	0.000306	CcSEcCtD
Azelastine—Ill-defined disorder—Epirubicin—prostate cancer	3.34e-05	0.000303	CcSEcCtD
Azelastine—Abdominal pain—Capecitabine—prostate cancer	3.34e-05	0.000302	CcSEcCtD
Azelastine—Body temperature increased—Capecitabine—prostate cancer	3.34e-05	0.000302	CcSEcCtD
Azelastine—Vomiting—Etoposide—prostate cancer	3.34e-05	0.000302	CcSEcCtD
Azelastine—Agitation—Epirubicin—prostate cancer	3.31e-05	0.0003	CcSEcCtD
Azelastine—Rash—Etoposide—prostate cancer	3.31e-05	0.0003	CcSEcCtD
Azelastine—Dermatitis—Etoposide—prostate cancer	3.31e-05	0.000299	CcSEcCtD
Azelastine—Headache—Etoposide—prostate cancer	3.29e-05	0.000298	CcSEcCtD
Azelastine—Tension—Doxorubicin—prostate cancer	3.27e-05	0.000296	CcSEcCtD
Azelastine—Dysgeusia—Doxorubicin—prostate cancer	3.27e-05	0.000296	CcSEcCtD
Azelastine—Prazepam—CYP3A4—prostate cancer	3.26e-05	0.0852	CrCbGaD
Azelastine—Malaise—Epirubicin—prostate cancer	3.25e-05	0.000294	CcSEcCtD
Azelastine—Fatigue—Prednisone—prostate cancer	3.24e-05	0.000294	CcSEcCtD
Azelastine—Nervousness—Doxorubicin—prostate cancer	3.24e-05	0.000293	CcSEcCtD
Azelastine—Vertigo—Epirubicin—prostate cancer	3.24e-05	0.000293	CcSEcCtD
Azelastine—Back pain—Doxorubicin—prostate cancer	3.23e-05	0.000292	CcSEcCtD
Azelastine—Constipation—Prednisone—prostate cancer	3.22e-05	0.000291	CcSEcCtD
Azelastine—Hypersensitivity—Docetaxel—prostate cancer	3.21e-05	0.000291	CcSEcCtD
Azelastine—Palpitations—Epirubicin—prostate cancer	3.19e-05	0.000289	CcSEcCtD
Azelastine—Cough—Epirubicin—prostate cancer	3.15e-05	0.000285	CcSEcCtD
Azelastine—Vision blurred—Doxorubicin—prostate cancer	3.14e-05	0.000285	CcSEcCtD
Azelastine—Asthenia—Docetaxel—prostate cancer	3.13e-05	0.000283	CcSEcCtD
Azelastine—Nausea—Etoposide—prostate cancer	3.12e-05	0.000282	CcSEcCtD
Azelastine—Hypertension—Epirubicin—prostate cancer	3.11e-05	0.000282	CcSEcCtD
Azelastine—Hypersensitivity—Capecitabine—prostate cancer	3.11e-05	0.000282	CcSEcCtD
Azelastine—Feeling abnormal—Prednisone—prostate cancer	3.1e-05	0.000281	CcSEcCtD
Azelastine—Ill-defined disorder—Doxorubicin—prostate cancer	3.09e-05	0.00028	CcSEcCtD
Azelastine—Pruritus—Docetaxel—prostate cancer	3.09e-05	0.000279	CcSEcCtD
Azelastine—Gastrointestinal pain—Prednisone—prostate cancer	3.08e-05	0.000279	CcSEcCtD
Azelastine—Chest pain—Epirubicin—prostate cancer	3.07e-05	0.000278	CcSEcCtD
Azelastine—Myalgia—Epirubicin—prostate cancer	3.07e-05	0.000278	CcSEcCtD
Azelastine—Agitation—Doxorubicin—prostate cancer	3.07e-05	0.000278	CcSEcCtD
Azelastine—Anxiety—Epirubicin—prostate cancer	3.06e-05	0.000277	CcSEcCtD
Azelastine—Discomfort—Epirubicin—prostate cancer	3.03e-05	0.000275	CcSEcCtD
Azelastine—Asthenia—Capecitabine—prostate cancer	3.03e-05	0.000274	CcSEcCtD
Azelastine—Malaise—Doxorubicin—prostate cancer	3.01e-05	0.000272	CcSEcCtD
Azelastine—Dry mouth—Epirubicin—prostate cancer	3e-05	0.000272	CcSEcCtD
Azelastine—Vertigo—Doxorubicin—prostate cancer	3e-05	0.000271	CcSEcCtD
Azelastine—Pruritus—Capecitabine—prostate cancer	2.99e-05	0.000271	CcSEcCtD
Azelastine—Diarrhoea—Docetaxel—prostate cancer	2.98e-05	0.00027	CcSEcCtD
Azelastine—Abdominal pain—Prednisone—prostate cancer	2.97e-05	0.000269	CcSEcCtD
Azelastine—Body temperature increased—Prednisone—prostate cancer	2.97e-05	0.000269	CcSEcCtD
Azelastine—Confusional state—Epirubicin—prostate cancer	2.97e-05	0.000269	CcSEcCtD
Azelastine—Palpitations—Doxorubicin—prostate cancer	2.95e-05	0.000267	CcSEcCtD
Azelastine—Anaphylactic shock—Epirubicin—prostate cancer	2.94e-05	0.000266	CcSEcCtD
Azelastine—Infection—Epirubicin—prostate cancer	2.92e-05	0.000265	CcSEcCtD
Azelastine—Cough—Doxorubicin—prostate cancer	2.91e-05	0.000264	CcSEcCtD
Azelastine—Diarrhoea—Capecitabine—prostate cancer	2.89e-05	0.000262	CcSEcCtD
Azelastine—Dizziness—Docetaxel—prostate cancer	2.88e-05	0.000261	CcSEcCtD
Azelastine—Hypertension—Doxorubicin—prostate cancer	2.88e-05	0.000261	CcSEcCtD
Azelastine—Tachycardia—Epirubicin—prostate cancer	2.87e-05	0.00026	CcSEcCtD
Azelastine—Chest pain—Doxorubicin—prostate cancer	2.84e-05	0.000257	CcSEcCtD
Azelastine—Myalgia—Doxorubicin—prostate cancer	2.84e-05	0.000257	CcSEcCtD
Azelastine—Anxiety—Doxorubicin—prostate cancer	2.83e-05	0.000256	CcSEcCtD
Azelastine—Discomfort—Doxorubicin—prostate cancer	2.81e-05	0.000254	CcSEcCtD
Azelastine—Dizziness—Capecitabine—prostate cancer	2.79e-05	0.000253	CcSEcCtD
Azelastine—Dry mouth—Doxorubicin—prostate cancer	2.78e-05	0.000252	CcSEcCtD
Azelastine—Vomiting—Docetaxel—prostate cancer	2.77e-05	0.000251	CcSEcCtD
Azelastine—Hypersensitivity—Prednisone—prostate cancer	2.77e-05	0.000251	CcSEcCtD
Azelastine—Rash—Docetaxel—prostate cancer	2.75e-05	0.000249	CcSEcCtD
Azelastine—Dermatitis—Docetaxel—prostate cancer	2.75e-05	0.000249	CcSEcCtD
Azelastine—Confusional state—Doxorubicin—prostate cancer	2.74e-05	0.000249	CcSEcCtD
Azelastine—Headache—Docetaxel—prostate cancer	2.73e-05	0.000247	CcSEcCtD
Azelastine—Anaphylactic shock—Doxorubicin—prostate cancer	2.72e-05	0.000247	CcSEcCtD
Azelastine—Infection—Doxorubicin—prostate cancer	2.7e-05	0.000245	CcSEcCtD
Azelastine—Asthenia—Prednisone—prostate cancer	2.7e-05	0.000244	CcSEcCtD
Azelastine—Vomiting—Capecitabine—prostate cancer	2.69e-05	0.000243	CcSEcCtD
Azelastine—Musculoskeletal discomfort—Epirubicin—prostate cancer	2.68e-05	0.000243	CcSEcCtD
Azelastine—Rash—Capecitabine—prostate cancer	2.66e-05	0.000241	CcSEcCtD
Azelastine—Pruritus—Prednisone—prostate cancer	2.66e-05	0.000241	CcSEcCtD
Azelastine—Dermatitis—Capecitabine—prostate cancer	2.66e-05	0.000241	CcSEcCtD
Azelastine—Tachycardia—Doxorubicin—prostate cancer	2.66e-05	0.000241	CcSEcCtD
Azelastine—Headache—Capecitabine—prostate cancer	2.65e-05	0.00024	CcSEcCtD
Azelastine—Paraesthesia—Epirubicin—prostate cancer	2.64e-05	0.000239	CcSEcCtD
Azelastine—Dyspnoea—Epirubicin—prostate cancer	2.62e-05	0.000238	CcSEcCtD
Azelastine—Somnolence—Epirubicin—prostate cancer	2.62e-05	0.000237	CcSEcCtD
Azelastine—Nausea—Docetaxel—prostate cancer	2.59e-05	0.000235	CcSEcCtD
Azelastine—Diarrhoea—Prednisone—prostate cancer	2.57e-05	0.000233	CcSEcCtD
Azelastine—Fatigue—Epirubicin—prostate cancer	2.54e-05	0.00023	CcSEcCtD
Azelastine—Pain—Epirubicin—prostate cancer	2.52e-05	0.000228	CcSEcCtD
Azelastine—Constipation—Epirubicin—prostate cancer	2.52e-05	0.000228	CcSEcCtD
Azelastine—Nausea—Capecitabine—prostate cancer	2.51e-05	0.000227	CcSEcCtD
Azelastine—Dizziness—Prednisone—prostate cancer	2.49e-05	0.000225	CcSEcCtD
Azelastine—Musculoskeletal discomfort—Doxorubicin—prostate cancer	2.48e-05	0.000225	CcSEcCtD
Azelastine—Paraesthesia—Doxorubicin—prostate cancer	2.44e-05	0.000221	CcSEcCtD
Azelastine—Dyspnoea—Doxorubicin—prostate cancer	2.43e-05	0.00022	CcSEcCtD
Azelastine—Feeling abnormal—Epirubicin—prostate cancer	2.42e-05	0.00022	CcSEcCtD
Azelastine—Somnolence—Doxorubicin—prostate cancer	2.42e-05	0.000219	CcSEcCtD
Azelastine—Gastrointestinal pain—Epirubicin—prostate cancer	2.41e-05	0.000218	CcSEcCtD
Azelastine—Vomiting—Prednisone—prostate cancer	2.39e-05	0.000217	CcSEcCtD
Azelastine—Clozapine—CYP3A4—prostate cancer	2.38e-05	0.0623	CrCbGaD
Azelastine—Rash—Prednisone—prostate cancer	2.37e-05	0.000215	CcSEcCtD
Azelastine—Dermatitis—Prednisone—prostate cancer	2.37e-05	0.000215	CcSEcCtD
Azelastine—Headache—Prednisone—prostate cancer	2.36e-05	0.000213	CcSEcCtD
Azelastine—Fatigue—Doxorubicin—prostate cancer	2.35e-05	0.000213	CcSEcCtD
Azelastine—Constipation—Doxorubicin—prostate cancer	2.33e-05	0.000211	CcSEcCtD
Azelastine—Pain—Doxorubicin—prostate cancer	2.33e-05	0.000211	CcSEcCtD
Azelastine—Abdominal pain—Epirubicin—prostate cancer	2.33e-05	0.000211	CcSEcCtD
Azelastine—Body temperature increased—Epirubicin—prostate cancer	2.33e-05	0.000211	CcSEcCtD
Azelastine—Feeling abnormal—Doxorubicin—prostate cancer	2.24e-05	0.000203	CcSEcCtD
Azelastine—Nausea—Prednisone—prostate cancer	2.23e-05	0.000202	CcSEcCtD
Azelastine—Gastrointestinal pain—Doxorubicin—prostate cancer	2.23e-05	0.000202	CcSEcCtD
Azelastine—Hypersensitivity—Epirubicin—prostate cancer	2.17e-05	0.000196	CcSEcCtD
Azelastine—Body temperature increased—Doxorubicin—prostate cancer	2.15e-05	0.000195	CcSEcCtD
Azelastine—Abdominal pain—Doxorubicin—prostate cancer	2.15e-05	0.000195	CcSEcCtD
Azelastine—Asthenia—Epirubicin—prostate cancer	2.11e-05	0.000191	CcSEcCtD
Azelastine—Pruritus—Epirubicin—prostate cancer	2.08e-05	0.000189	CcSEcCtD
Azelastine—Diarrhoea—Epirubicin—prostate cancer	2.01e-05	0.000182	CcSEcCtD
Azelastine—Hypersensitivity—Doxorubicin—prostate cancer	2.01e-05	0.000182	CcSEcCtD
Azelastine—Asthenia—Doxorubicin—prostate cancer	1.95e-05	0.000177	CcSEcCtD
Azelastine—Dizziness—Epirubicin—prostate cancer	1.95e-05	0.000176	CcSEcCtD
Azelastine—Pruritus—Doxorubicin—prostate cancer	1.93e-05	0.000174	CcSEcCtD
Azelastine—Vomiting—Epirubicin—prostate cancer	1.87e-05	0.000169	CcSEcCtD
Azelastine—Diarrhoea—Doxorubicin—prostate cancer	1.86e-05	0.000169	CcSEcCtD
Azelastine—Rash—Epirubicin—prostate cancer	1.86e-05	0.000168	CcSEcCtD
Azelastine—Dermatitis—Epirubicin—prostate cancer	1.85e-05	0.000168	CcSEcCtD
Azelastine—Headache—Epirubicin—prostate cancer	1.84e-05	0.000167	CcSEcCtD
Azelastine—Dizziness—Doxorubicin—prostate cancer	1.8e-05	0.000163	CcSEcCtD
Azelastine—Nausea—Epirubicin—prostate cancer	1.75e-05	0.000158	CcSEcCtD
Azelastine—Vomiting—Doxorubicin—prostate cancer	1.73e-05	0.000157	CcSEcCtD
Azelastine—Rash—Doxorubicin—prostate cancer	1.72e-05	0.000155	CcSEcCtD
Azelastine—Dermatitis—Doxorubicin—prostate cancer	1.71e-05	0.000155	CcSEcCtD
Azelastine—Headache—Doxorubicin—prostate cancer	1.71e-05	0.000154	CcSEcCtD
Azelastine—Nausea—Doxorubicin—prostate cancer	1.62e-05	0.000146	CcSEcCtD
Azelastine—HRH1—Signaling Pathways—INS—prostate cancer	1.21e-06	1.31e-05	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—INS—prostate cancer	1.21e-06	1.31e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—AKR1C3—prostate cancer	1.21e-06	1.31e-05	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—PIK3CG—prostate cancer	1.21e-06	1.31e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—PRKACB—prostate cancer	1.2e-06	1.3e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—LPL—prostate cancer	1.2e-06	1.3e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—LPL—prostate cancer	1.19e-06	1.29e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—FGF2—prostate cancer	1.19e-06	1.29e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—CYP17A1—prostate cancer	1.19e-06	1.29e-05	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—CREBBP—prostate cancer	1.19e-06	1.29e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—CREBBP—prostate cancer	1.19e-06	1.28e-05	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—CREBBP—prostate cancer	1.19e-06	1.28e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—RXRA—prostate cancer	1.18e-06	1.27e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—MTHFR—prostate cancer	1.18e-06	1.27e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—NOS3—prostate cancer	1.18e-06	1.27e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—IGF1—prostate cancer	1.17e-06	1.27e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling by GPCR—EGFR—prostate cancer	1.17e-06	1.26e-05	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	1.16e-06	1.26e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—CYP1A1—prostate cancer	1.16e-06	1.26e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—PPARA—prostate cancer	1.16e-06	1.25e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—ERCC2—prostate cancer	1.15e-06	1.25e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—CYP1A1—prostate cancer	1.15e-06	1.24e-05	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—PIK3CD—prostate cancer	1.15e-06	1.24e-05	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—MTHFR—prostate cancer	1.15e-06	1.24e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	1.15e-06	1.24e-05	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—INS—prostate cancer	1.15e-06	1.24e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—ERCC2—prostate cancer	1.14e-06	1.23e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—JAK2—prostate cancer	1.14e-06	1.23e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—COMT—prostate cancer	1.14e-06	1.23e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—NCOA2—prostate cancer	1.14e-06	1.23e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—MAP2K1—prostate cancer	1.13e-06	1.22e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—GSTP1—prostate cancer	1.13e-06	1.22e-05	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—PPARA—prostate cancer	1.13e-06	1.22e-05	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—PIK3CD—prostate cancer	1.13e-06	1.22e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—PIK3CD—prostate cancer	1.13e-06	1.22e-05	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—PIK3CD—prostate cancer	1.13e-06	1.22e-05	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—CREBBP—prostate cancer	1.12e-06	1.21e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling by GPCR—PIK3CA—prostate cancer	1.12e-06	1.21e-05	CbGpPWpGaD
Azelastine—HRH1—GPCR downstream signaling—PIK3CA—prostate cancer	1.12e-06	1.21e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—MDM2—prostate cancer	1.11e-06	1.2e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—SERPINE1—prostate cancer	1.11e-06	1.2e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—ITPR1—prostate cancer	1.11e-06	1.2e-05	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—PIK3CG—prostate cancer	1.11e-06	1.2e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling by GPCR—KRAS—prostate cancer	1.1e-06	1.19e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—ERBB2—prostate cancer	1.1e-06	1.19e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism of lipids and lipoproteins—EP300—prostate cancer	1.09e-06	1.18e-05	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—NOS3—prostate cancer	1.09e-06	1.17e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—CAV1—prostate cancer	1.09e-06	1.17e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—PIK3CB—prostate cancer	1.08e-06	1.17e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—MTHFR—prostate cancer	1.08e-06	1.17e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—SLC5A5—prostate cancer	1.08e-06	1.17e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—FGF2—prostate cancer	1.08e-06	1.17e-05	CbGpPWpGaD
Azelastine—CYP2A6—Metabolism—PTEN—prostate cancer	1.07e-06	1.16e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—MTHFR—prostate cancer	1.07e-06	1.16e-05	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—NOS3—prostate cancer	1.07e-06	1.15e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—NOS3—prostate cancer	1.06e-06	1.15e-05	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—PIK3CD—prostate cancer	1.06e-06	1.15e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—PPARA—prostate cancer	1.06e-06	1.15e-05	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—NOS3—prostate cancer	1.06e-06	1.15e-05	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—CAV1—prostate cancer	1.06e-06	1.15e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—CYP2E1—prostate cancer	1.06e-06	1.14e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—PPARA—prostate cancer	1.05e-06	1.14e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—TYMS—prostate cancer	1.05e-06	1.14e-05	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—INS—prostate cancer	1.05e-06	1.13e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—NQO1—prostate cancer	1.05e-06	1.13e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—CXCL8—prostate cancer	1.04e-06	1.13e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—GSTM1—prostate cancer	1.04e-06	1.12e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	1.04e-06	1.12e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—JAK2—prostate cancer	1.03e-06	1.12e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—TH—prostate cancer	1.03e-06	1.11e-05	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—CREBBP—prostate cancer	1.03e-06	1.11e-05	CbGpPWpGaD
Azelastine—CYP2A6—Metabolism—EP300—prostate cancer	1.03e-06	1.11e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—LPL—prostate cancer	1.02e-06	1.1e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—CDKN1B—prostate cancer	1.02e-06	1.1e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling by GPCR—PIK3CA—prostate cancer	1.01e-06	1.09e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—MDM2—prostate cancer	1.01e-06	1.09e-05	CbGpPWpGaD
Azelastine—ADRA1B—GPCR downstream signaling—AKT1—prostate cancer	1.01e-06	1.09e-05	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—NOS3—prostate cancer	1e-06	1.08e-05	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—PIK3CB—prostate cancer	1e-06	1.08e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—CYP1B1—prostate cancer	1e-06	1.08e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—CAV1—prostate cancer	1e-06	1.08e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—CASP3—prostate cancer	9.98e-07	1.08e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—IL2—prostate cancer	9.96e-07	1.08e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—ERBB2—prostate cancer	9.95e-07	1.07e-05	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—PTGS2—prostate cancer	9.95e-07	1.07e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling by GPCR—IL6—prostate cancer	9.91e-07	1.07e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—CAV1—prostate cancer	9.91e-07	1.07e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—PIK3CG—prostate cancer	9.9e-07	1.07e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—CYP1A1—prostate cancer	9.85e-07	1.06e-05	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—PIK3CB—prostate cancer	9.83e-07	1.06e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—PIK3CB—prostate cancer	9.82e-07	1.06e-05	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—PIK3CB—prostate cancer	9.81e-07	1.06e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—ERCC2—prostate cancer	9.77e-07	1.05e-05	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—PIK3CD—prostate cancer	9.75e-07	1.05e-05	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—PTGS2—prostate cancer	9.74e-07	1.05e-05	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—PTGS2—prostate cancer	9.72e-07	1.05e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—GGT1—prostate cancer	9.71e-07	1.05e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—CCND1—prostate cancer	9.71e-07	1.05e-05	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—PIK3CG—prostate cancer	9.66e-07	1.04e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—CTNNB1—prostate cancer	9.62e-07	1.04e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—NCOA1—prostate cancer	9.57e-07	1.03e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	9.47e-07	1.02e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—CXCL8—prostate cancer	9.44e-07	1.02e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—MMP9—prostate cancer	9.43e-07	1.02e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—CYP19A1—prostate cancer	9.43e-07	1.02e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—CDKN1A—prostate cancer	9.39e-07	1.01e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—PTEN—prostate cancer	9.37e-07	1.01e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—INS—prostate cancer	9.37e-07	1.01e-05	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—PIK3CB—prostate cancer	9.27e-07	1e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—CDKN1B—prostate cancer	9.21e-07	9.95e-06	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—NOS3—prostate cancer	9.21e-07	9.94e-06	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—PTGS2—prostate cancer	9.18e-07	9.92e-06	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—MTHFR—prostate cancer	9.18e-07	9.92e-06	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—CREBBP—prostate cancer	9.18e-07	9.91e-06	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—INS—prostate cancer	9.15e-07	9.88e-06	CbGpPWpGaD
Azelastine—ADRA1B—Signaling by GPCR—AKT1—prostate cancer	9.14e-07	9.88e-06	CbGpPWpGaD
Azelastine—HRH1—GPCR downstream signaling—AKT1—prostate cancer	9.11e-07	9.85e-06	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—PIK3CG—prostate cancer	9.1e-07	9.83e-06	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—RXRA—prostate cancer	9.1e-07	9.83e-06	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—CASP3—prostate cancer	9.03e-07	9.76e-06	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—PIK3CG—prostate cancer	9.03e-07	9.75e-06	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—IL2—prostate cancer	9.02e-07	9.74e-06	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—PPARA—prostate cancer	9.01e-07	9.73e-06	CbGpPWpGaD
Azelastine—HRH1—Signaling by GPCR—IL6—prostate cancer	8.97e-07	9.69e-06	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—CREBBP—prostate cancer	8.96e-07	9.68e-06	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—EP300—prostate cancer	8.94e-07	9.66e-06	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—CCND1—prostate cancer	8.79e-07	9.5e-06	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—COMT—prostate cancer	8.76e-07	9.47e-06	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—GSTP1—prostate cancer	8.72e-07	9.42e-06	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—CTNNB1—prostate cancer	8.7e-07	9.4e-06	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—PIK3CD—prostate cancer	8.7e-07	9.4e-06	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—SRC—prostate cancer	8.69e-07	9.39e-06	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—PTEN—prostate cancer	8.67e-07	9.37e-06	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—INS—prostate cancer	8.62e-07	9.31e-06	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—ITPR1—prostate cancer	8.58e-07	9.27e-06	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—INS—prostate cancer	8.54e-07	9.23e-06	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—MMP9—prostate cancer	8.53e-07	9.22e-06	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—CDKN1A—prostate cancer	8.5e-07	9.19e-06	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—PIK3CB—prostate cancer	8.5e-07	9.18e-06	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—PTEN—prostate cancer	8.49e-07	9.18e-06	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—PIK3CD—prostate cancer	8.49e-07	9.17e-06	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—PTEN—prostate cancer	8.48e-07	9.17e-06	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—PTEN—prostate cancer	8.48e-07	9.16e-06	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—CAV1—prostate cancer	8.47e-07	9.15e-06	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—VEGFA—prostate cancer	8.47e-07	9.15e-06	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—CREBBP—prostate cancer	8.44e-07	9.12e-06	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—PTGS2—prostate cancer	8.42e-07	9.1e-06	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—STAT3—prostate cancer	8.38e-07	9.06e-06	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—CREBBP—prostate cancer	8.37e-07	9.04e-06	CbGpPWpGaD
Azelastine—HRH1—Signaling by GPCR—AKT1—prostate cancer	8.28e-07	8.94e-06	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—EP300—prostate cancer	8.27e-07	8.94e-06	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—NOS3—prostate cancer	8.22e-07	8.88e-06	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—TYMS—prostate cancer	8.11e-07	8.76e-06	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—EP300—prostate cancer	8.1e-07	8.75e-06	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—EP300—prostate cancer	8.09e-07	8.74e-06	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	8.09e-07	8.74e-06	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—EP300—prostate cancer	8.08e-07	8.73e-06	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—NOS3—prostate cancer	8.02e-07	8.66e-06	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—GSTM1—prostate cancer	8.02e-07	8.66e-06	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—PTEN—prostate cancer	8.01e-07	8.65e-06	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—PIK3CD—prostate cancer	8e-07	8.65e-06	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—PIK3CD—prostate cancer	7.93e-07	8.57e-06	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—LPL—prostate cancer	7.87e-07	8.5e-06	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—SRC—prostate cancer	7.87e-07	8.5e-06	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—MYC—prostate cancer	7.79e-07	8.41e-06	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—TGFB1—prostate cancer	7.77e-07	8.39e-06	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—PIK3CG—prostate cancer	7.71e-07	8.33e-06	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—VEGFA—prostate cancer	7.66e-07	8.28e-06	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—EP300—prostate cancer	7.64e-07	8.25e-06	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—EGFR—prostate cancer	7.62e-07	8.23e-06	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—CYP1A1—prostate cancer	7.6e-07	8.21e-06	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—STAT3—prostate cancer	7.59e-07	8.2e-06	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—PIK3CB—prostate cancer	7.58e-07	8.19e-06	CbGpPWpGaD
Azelastine—CYP2A6—Metabolism—PIK3CA—prostate cancer	7.58e-07	8.19e-06	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—NOS3—prostate cancer	7.56e-07	8.16e-06	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—ERCC2—prostate cancer	7.54e-07	8.14e-06	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—PTGS2—prostate cancer	7.52e-07	8.12e-06	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—NOS3—prostate cancer	7.49e-07	8.09e-06	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—PIK3CB—prostate cancer	7.4e-07	8e-06	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—PTEN—prostate cancer	7.34e-07	7.93e-06	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—PTGS2—prostate cancer	7.34e-07	7.92e-06	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—INS—prostate cancer	7.3e-07	7.89e-06	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—KRAS—prostate cancer	7.2e-07	7.77e-06	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—CREBBP—prostate cancer	7.15e-07	7.72e-06	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—MTHFR—prostate cancer	7.08e-07	7.65e-06	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—MYC—prostate cancer	7.05e-07	7.62e-06	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—TGFB1—prostate cancer	7.03e-07	7.6e-06	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—EP300—prostate cancer	7e-07	7.56e-06	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—PIK3CB—prostate cancer	6.98e-07	7.54e-06	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—PPARA—prostate cancer	6.95e-07	7.51e-06	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—PIK3CB—prostate cancer	6.92e-07	7.47e-06	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—PTGS2—prostate cancer	6.91e-07	7.47e-06	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—EGFR—prostate cancer	6.9e-07	7.45e-06	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—PTGS2—prostate cancer	6.85e-07	7.4e-06	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—PIK3CD—prostate cancer	6.78e-07	7.32e-06	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—PIK3CA—prostate cancer	6.61e-07	7.14e-06	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—PTEN—prostate cancer	6.55e-07	7.08e-06	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—CAV1—prostate cancer	6.53e-07	7.06e-06	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—KRAS—prostate cancer	6.51e-07	7.04e-06	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—NOS3—prostate cancer	6.4e-07	6.92e-06	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—PTEN—prostate cancer	6.4e-07	6.91e-06	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—TP53—prostate cancer	6.4e-07	6.91e-06	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—EP300—prostate cancer	6.25e-07	6.75e-06	CbGpPWpGaD
Azelastine—CYP2A6—Metabolism—AKT1—prostate cancer	6.2e-07	6.69e-06	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—PIK3CA—prostate cancer	6.12e-07	6.61e-06	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—EP300—prostate cancer	6.1e-07	6.59e-06	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—PTEN—prostate cancer	6.03e-07	6.51e-06	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—PIK3CA—prostate cancer	5.99e-07	6.47e-06	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—PIK3CA—prostate cancer	5.99e-07	6.47e-06	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—PIK3CA—prostate cancer	5.98e-07	6.46e-06	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—PTEN—prostate cancer	5.98e-07	6.46e-06	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—PIK3CG—prostate cancer	5.95e-07	6.43e-06	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—PIK3CB—prostate cancer	5.91e-07	6.38e-06	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—PTGS2—prostate cancer	5.86e-07	6.33e-06	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—IL6—prostate cancer	5.86e-07	6.33e-06	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—TP53—prostate cancer	5.79e-07	6.25e-06	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—EP300—prostate cancer	5.75e-07	6.21e-06	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—EP300—prostate cancer	5.7e-07	6.16e-06	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—PIK3CA—prostate cancer	5.65e-07	6.1e-06	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—INS—prostate cancer	5.63e-07	6.09e-06	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—CREBBP—prostate cancer	5.52e-07	5.96e-06	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—AKT1—prostate cancer	5.4e-07	5.84e-06	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—IL6—prostate cancer	5.3e-07	5.73e-06	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—PIK3CD—prostate cancer	5.23e-07	5.65e-06	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—PIK3CA—prostate cancer	5.18e-07	5.6e-06	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—PTEN—prostate cancer	5.11e-07	5.52e-06	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—AKT1—prostate cancer	5e-07	5.4e-06	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—NOS3—prostate cancer	4.94e-07	5.34e-06	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—AKT1—prostate cancer	4.9e-07	5.29e-06	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—AKT1—prostate cancer	4.89e-07	5.28e-06	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—AKT1—prostate cancer	4.89e-07	5.28e-06	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—EP300—prostate cancer	4.87e-07	5.26e-06	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—PIK3CA—prostate cancer	4.62e-07	4.99e-06	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—AKT1—prostate cancer	4.62e-07	4.99e-06	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—PIK3CB—prostate cancer	4.56e-07	4.93e-06	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—PTGS2—prostate cancer	4.52e-07	4.88e-06	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—PIK3CA—prostate cancer	4.51e-07	4.88e-06	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—PIK3CA—prostate cancer	4.25e-07	4.59e-06	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—AKT1—prostate cancer	4.23e-07	4.57e-06	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—PIK3CA—prostate cancer	4.22e-07	4.55e-06	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—PTEN—prostate cancer	3.94e-07	4.26e-06	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—AKT1—prostate cancer	3.78e-07	4.08e-06	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—EP300—prostate cancer	3.76e-07	4.06e-06	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—AKT1—prostate cancer	3.69e-07	3.98e-06	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—PIK3CA—prostate cancer	3.6e-07	3.89e-06	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—AKT1—prostate cancer	3.47e-07	3.75e-06	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—AKT1—prostate cancer	3.44e-07	3.72e-06	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—AKT1—prostate cancer	2.94e-07	3.18e-06	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—PIK3CA—prostate cancer	2.78e-07	3e-06	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—AKT1—prostate cancer	2.27e-07	2.45e-06	CbGpPWpGaD
